CRMD:NASDAQCorMedix Inc. Analysis

CorMedix (CRMD) is trading at $6.70, well below its 20‑day SMA of 6.60 and far under the 200‑day SMA of 10.57, indicating a steep downtrend that nonetheless leaves room for a bounce toward the 7.27 resistance level. The stock sits just above the calculated support of 6.13, with a neutral‑ish RSI of 47 and a MACD histogram turning positive (0.07), suggesting a tentative technical recovery despite an overall bearish trend. Fundamentals are strikingly strong: revenue of $311.7M grew over 300% year‑over‑year, gross margin exceeds 92%, operating margin is above 54%, and ROE is an impressive 66%. The company’s PE of 3.28 dwarfs the biotech industry average of 25.47, and a DCF fair‑value estimate of $50.68 implies an upside of more than 115%. Recent earnings calls highlighted DefenCath sales approaching $260M and the strategic acquisition of Melinta Therapeutics, while analysts such as Truist have reiterated a Buy rating with a $16 price target, reinforcing the growth narrative.
The risk profile is tempered by a high 30‑day volatility of 47% and a beta under 1, indicating sensitivity to market swings but less systematic risk than the broader market. Volume trends are decreasing, pointing to waning liquidity, and the biotech sector carries inherent regulatory and clinical‑trial uncertainties. Nonetheless, the combination of deep discount to intrinsic value, robust cash generation (free cash flow > $108M), and positive product momentum supports a favorable outlook across horizons.